Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

Experimental Hematology

Volumn 41, Issue 1, 2013, Pages

  Zhang, Kejie ^a,b   Wang, Michael ^a   Tamayo, Archito T ^a   Shacham, Sharon ^c   Kauffman, Michael ^c   Lee, John ^a   Zhang, Liang ^a   Ou, Zhishuo ^a   Li, Changping ^a   Sun, Luhong ^a   Ford, Richard J ^a   Pham, Lan V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b XIAMEN UNIVERSITY   (China)

^c Karyopharm Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EXPORTIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KPT 185; KPT 276; PROTEASOME; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 84870887672     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.09.002     Document Type: Article

References (49)

1. Lardelli P., Bookman M.A., Sundeen J., Longo D.L., Jaffe E.S. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 1990, 14:752-763.
2. Levine P.H., Hoover R. The emerging epidemic of non-Hodgkin's lymphoma: current knowledge regarding etiological factors. Cancer Epidemiol Biomarkers Prev 1992, 1:515-517.
3. Herrmann A., Hoster E., Zwingers T., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009, 27:511-518.
4. Martin P., Chadburn A., Christos P., et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008, 19:1327-1330.
5. Bodrug S.E., Warner B.J., Bath M.L., Lindeman G.J., Harris A.W., Adams J.M. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994, 13:2124-2130.
6. Adachi Y., Yanagida M. Higher order chromosome structure is affected by cold-sensitive mutations in a Schizosaccharomyces pombe gene crm1+ which encodes a 115-kD protein preferentially localized in the nucleus and its periphery. J Cell Biol 1989, 108:1195-1207.
7. Kudo N., Khochbin S., Nishi K., et al. Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J Biol Chem 1997, 272:29742-29751.
8. Stade K., Ford C.S., Guthrie C., Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997, 90:1041-1050.
9. Yoshida M., Horinouchi S. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann N Y Acad Sci 1999, 886:23-36.
10. Gallouzi I.E., Steitz J.A. Delineation of mRNA export pathways by the use of cell-permeable peptides. Science 2001, 294:1895-1901.
11. Jang B.C., Munoz-Najar U., Paik J.H., Claffey K., Yoshida M., Hla T. Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression. J Biol Chem 2003, 278:2773-2776.
12. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999, 18:1660-1672.
13. Harrison B.C., Roberts C.R., Hood D.B., et al. The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol 2004, 24:10636-10649.
14. Saji M., Vasko V., Kada F., Allbritton E.H., Burman K.D., Ringel M.D. Akt1 contains a functional leucine-rich nuclear export sequence. Biochem Biophys Res Commun 2005, 332:167-173.
15. Lo H.W., Ali-Seyed M., Wu Y., Bartholomeusz G., Hsu S.C., Hung M.C. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 2006, 98:1570-1583.
16. Bartholomeusz G., Wu Y., Ali Seyed M., et al. Nuclear translocation of the pro-apoptotic Bcl-2 family member Bok induces apoptosis. Mol Carcinog 2006, 45:73-83.
17. Toone W.M., Kuge S., Samuels M., Morgan B.A., Toda T., Jones N. Regulation of the fission yeast transcription factor Pap1 by oxidative stress: requirement for the nuclear export factor Crm1 (Exportin) and the stress-activated MAP kinase Sty1/Spc1. Genes Dev 1998, 12:1453-1463.
18. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83:1021-1032.
19. Yashiroda Y., Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 2003, 10:741-748.
20. Turner J.G., Sullivan D.M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 2008, 15:2648-2655.
21. Gray L.J., Bjelogrlic P., Appleyard V.C., et al. Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes. Int J Cancer 2007, 120:2317-2324.
22. Yang J.Y., Hung M.C. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 2009, 15:752-757.
23. Dey A., Tergaonkar V., Lane D.P. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov 2008, 7:1031-1040.
24. Kudo N., Matsumori N., Taoka H., et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 1999, 96:9112-9117.
25. Newlands E.S., Rustin G.J., Brampton M.H. Phase I trial of elactocin. Br J Cancer 1996, 74:648-649.
26. Mutka S.C., Yang W.Q., Dong S.D., et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009, 69:510-517.
27. Fu L., Lin-Lee Y.C., Pham L.V., Tamayo A., Yoshimura L., Ford R.J. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 2006, 107:4540-4548.
28. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., Ford R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003, 171:88-95.
29. Basso K., Margolin A.A., Stolovitzky G., Klein U., Dalla-Favera R., Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005, 37:382-390.
30. Lapalombella R., Berglund C., Mahoney E., et al. CRM1/XPO1 represents a promising therapeutic target for treatment of chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 2011, 118:232.
31. Kandarpa M., Kraftson S.J., Maxwell S.P., et al. CRM1 Is highly expressed in myeloma plasma cells and its inhibition byKPT-SINE induces cytotoxicity by increasing p53 in the nucleus of multiple myeloma (MM) cells. ASH Annual Meeting Abstracts 2011, 118:1852.
32. Fornerod M., van Deursen J., van Baal S., et al. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J 1997, 16:807-816.
33. Turner J.G., Marchion D.C., Dawson J.L., et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009, 69:6899-6905.
34. Goldberg A.L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007, 35:12-17.
35. Huang T.T., Kudo N., Yoshida M., Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci U S A 2000, 97:1014-1019.
36. van der Watt P.J., Maske C.P., Hendricks D.T., et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009, 124:1829-1840.
37. Noske A., Weichert W., Niesporek S., et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 2008, 112:1733-1743.
38. Puente X.S., Pinyol M., Quesada V., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
39. Wach J.Y., Guttinger S., Kutay U., Gademann K. The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg Med Chem Lett 2010, 20:2843-2846.
40. Bonazzi S., Eidam O., Guttinger S., et al. Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. J Am Chem Soc 2010, 132:1432-1442.
41. Sakakibara K., Saito N., Sato T., et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011, 118:3922-3931.
42. Van Neck T., Pannecouque C., Vanstreels E., Stevens M., Dehaen W., Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 2008, 16:9487-9497.
43. Kau T.R., Schroeder F., Ramaswamy S., et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003, 4:463-476.
44. Darnell J.E. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002, 2:740-749.
45. Keller S.A., Schattner E.J., Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000, 96:2537-2542.
46. Cahir-McFarland E.D., Davidson D.M., Schauer S.L., Duong J., Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A 2000, 97:6055-6060.
47. Chiao P.J., Miyamoto S., Verma I.M. Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci U S A 1994, 91:28-32.
48. Arenzana-Seisdedos F., Turpin P., Rodriguez M., et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997, 110(Pt 3):369-378.
49. O'Connor S., Shumway S., Miyamoto S. Inhibition of IkappaBalpha nuclear export as an approach to abrogate nuclear factor-kappaB-dependent cancer cell survival. Mol Cancer Res 2005, 3:42-49.